Jeremy Barton, MD

Jeremy Barton, M.D. has over 33 years of global experience in all phases of oncology drug development in the pharmaceutical industry. He now advises biotech companies on strategic oncology drug development focusing on the efficient transition from preclinical research to proof-of-concept in the clinic

Most recent industry responsibilities have included Chief Medical Officer roles at Biogen Idec, eFFECTOR Therapeutics and Mirati Therapeutics. Dr. Barton was also head of early Oncology Development at Pfizer (San Diego) for 5 years overseeing the transition of all oncology compounds from research through IND to proof-of-concept studies.

After obtaining a Masters Degree in Physiological Sciences from Oxford University, and his medical degree at University College Hospital Medical School in London, Dr. Barton trained in Internal Medicine and Clinical Oncology in the United Kingdom and practiced for 11 years in the National Health Service.

Dr. Barton is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians (U.K.), a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of the Faculty of Pharmaceutical Medicine.